Phamaceutical company Takeda has invested $25m and entered into a strategic partnership with biotech company BioMotiv.

Japan-based pharmaceutical company Takeda Pharmaceutical has agreed to invest $25m in BioMotiv, the US-based biotech accelerator associated with The Harrington Project for Discovery & Development BioMoti.  

Takeda will invest the cash over five years as part of a strategic agreement that will give it exclusive rights to any programmes sourced by BioMotiv in the areas of immunology and inflammation, and cardio-metabolic diseases. The partnership will also involve the two companies working together to develop medical innovations. 

Baiju R. Shah, BioMotiv’s…